PLA2G12A rs2285714: What Your Genotype Means
The rs2285714 variant is a single nucleotide polymorphism located within the PLA2G12A gene. It has been studied for its potential association with how individuals with exudative age-related macular degeneration (AMD) respond to anti-VEGF medical therapies.
What each genotype means
Potential favorable therapy response
Research suggests that individuals without the T allele may be more likely to be classified as good responders to anti-VEGF therapy for exudative age-related macular degeneration. This association is based on limited data and requires further confirmation in larger studies. Please discuss your treatment plan and expectations for therapy response with your ophthalmologist.
This genotype is common, though exact frequencies vary by ancestral background.
Potential reduced therapy response
Studies have indicated that carrying at least one T allele may be associated with a higher likelihood of being a poor responder to anti-VEGF therapy for exudative age-related macular degeneration compared to those without the allele. This finding is considered suggestive and has not been definitively proven across all populations. You should discuss your specific clinical situation and treatment options with your eye care specialist.
This heterozygous genotype is frequently observed in many global populations.
Potential reduced therapy response
Carrying two copies of the T allele has been associated in some research with a higher probability of being a poor responder to anti-VEGF therapy for exudative age-related macular degeneration. Because this evidence is based on small study cohorts, it should be interpreted with caution and not used to guide clinical decisions independently. Always consult with your clinician regarding your prognosis and therapeutic choices.
This genotype is present at moderate frequencies across various ancestral groups.
Understanding the rs2285714 Variant
The rs2285714 variant is a specific change in the DNA sequence, known as a single nucleotide polymorphism (SNP), located within the PLA2G12A gene. In genetics, a SNP represents a variation at a single position in the DNA chain. Researchers study these variations to determine if they correlate with specific physical traits or responses to medical treatments. Because the human genome is vast, identifying these specific markers helps scientists narrow down which regions of our DNA might influence complex biological processes. In the case of rs2285714, the focus has been on its potential role in the eye, specifically regarding how patients with exudative age-related macular degeneration (AMD) react to standard anti-VEGF treatments. It is important to note that this variant is just one of many genetic factors that may influence health outcomes, and its presence does not determine a specific medical outcome on its own.
The Role of the PLA2G12A Gene
The PLA2G12A gene encodes for a protein known as phospholipase A2 group XIIA. This protein belongs to a family of enzymes that play a critical role in lipid metabolism. Specifically, these enzymes are responsible for liberating arachidonic acid from phospholipids, which is a key step in the production of eicosanoids. Eicosanoids are signaling molecules that participate in various physiological processes, including inflammation and vascular regulation. Because the development of exudative AMD involves complex processes like angiogenesis—the formation of new blood vessels—and inflammation, researchers have hypothesized that variations in genes involved in lipid signaling, such as PLA2G12A, might influence the severity of the disease or the effectiveness of therapies designed to inhibit vascular endothelial growth factor (VEGF). Understanding the function of this gene provides a biological basis for why scientists investigate its variants in the context of retinal health.
Research and Evidence Strength
The evidence linking rs2285714 to anti-VEGF treatment response is currently considered suggestive or moderate. Early studies, such as those published in Molecular Vision, have explored whether this SNP could serve as a predictive biomarker for how well patients respond to anti-VEGF injections. In these studies, researchers compared the frequency of the minor allele in patients classified as 'good responders' versus 'poor responders.' While some data have indicated a potential difference in allele frequency between these groups, the findings have not been definitive. Statistical associations in these studies often show wide confidence intervals, and the p-values suggest that the findings require validation in larger, independent cohorts. Consequently, the scientific community views this association as a starting point for further investigation rather than a confirmed clinical tool. It is essential to recognize that genetic associations are often complex and influenced by many other genes and environmental factors.
Clinical Implications and Next Steps
It is vital to understand that the information regarding rs2285714 is for educational purposes and should not be used to make medical decisions. Genetic variants are rarely the sole cause of a treatment response, and many other factors—including age, overall health, and the specific stage of eye disease—play significant roles. If you are undergoing treatment for age-related macular degeneration, you should never alter your medication or treatment plan based on genetic test results without consulting your ophthalmologist or a qualified healthcare provider. Your clinician is the only person who can interpret how your unique health profile, including any genetic information, might relate to your care. If you are curious about how your genetics might influence your treatment, bring your questions to your next appointment. They can provide context on the current standard of care and explain why certain therapies are recommended for your specific situation.
How common is this variant?
The rs2285714 variant is considered a common SNP across various human populations. Specific allele frequencies can vary by ancestry, but it is generally well-represented in genomic databases.
Frequently asked questions
Can I use a genetic test to predict if anti-VEGF therapy will work for me?
Currently, there is no clinically validated genetic test that can definitively predict your response to anti-VEGF therapy. While research into variants like rs2285714 is ongoing, these findings are not yet used to guide routine clinical treatment.
What is the PLA2G12A gene responsible for?
The PLA2G12A gene provides instructions for making an enzyme involved in lipid metabolism. This enzyme helps release fatty acids that are important for signaling pathways related to inflammation and blood vessel growth.
Is rs2285714 a cause of macular degeneration?
No, rs2285714 is not considered a direct cause of age-related macular degeneration. It is a genetic marker that has been studied for its potential association with how patients respond to treatment, not as a primary cause of the disease itself.
Should I get tested for this SNP?
There is no medical recommendation to get tested for this specific SNP. Because the evidence is only suggestive and not clinically actionable, testing would not change your current treatment plan or medical management.
Sources & further reading
Educational information only, last refreshed 9/22/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2285714?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29